AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28665051
Drug: Veliparib 400
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib 400 mg
Trial: 28665051
Drug: Veliparib 200
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib 200 mg
Trial: 25752115
Drug: Tympanic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tympanic injection of triamcinolone acetonide, administered 1 hour before radiotherapy, once a week for 1-7 weeks (treatment group I)
Trial: 25752115
Drug: Tympanic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tympanic injection of triamcinolone acetonide, administered 1 hour before radiotherapy, once a week for 1-12 weeks (treatment group II)
Trial: 25752115
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no tympanic injection of triamcinolone acetonide)
Trial: 14520857
Drug: Thyroxine (TX)
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thyroxine (TX) 75-150 mcg/day
Trial: 14520857
Drug: Potassium Iodide
RxNorm normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potassium Iodide (PI) 200 mcg/day
Trial: 8882258
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg at induction of anaesthesia, repeated 8 h later
Trial: 31120108
Drug: Automated matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated matched saline infusion with urine output (active group)
Trial: 26509681
Drug: Wireless patch
RxNorm normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wireless patch
Trial: 26509681
Drug: Wired dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wired dose controller
Trial: 26509681
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (Wireless patch and Wired dose controller)
Trial: 23417645
Drug: Postoperative inpatient
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative inpatient exercise program (twice daily exercise including stretching, core, balance, and low-intensity resistance exercises)
Trial: 24499517
Drug: Once-daily insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily insulin detemir
Trial: 18945928
Drug: Twice-daily insulin
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily insulin detemir
Trial: 16014056
Drug: Initial statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial statin treatment
Trial: 7138748
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drugs (NSAID), given three times daily for a week.
Trial: 7138748
Drug: NSAID treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID treatment (specific drugs not detailed), randomized order of administration.
Trial: 31800960
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine A (CsA) 0.05% for 4 weeks
Trial: 31800960
Drug: Topical diquafosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diquafosol tetrasodium (DQS) 3% for 4 weeks
Trial: 27885751
Drug: Cardiac Resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronization Therapy with Defibrillation (CRT-D)
Trial: 27885751
Drug: Cardiac Resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronization Therapy with Defibrillation (CRT-D) in prolonged baseline PR interval subgroup
Trial: 22190528
Drug: Compound anisodine
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound anisodine injection (CA group)
Trial: 22190528
Drug: Venoruton tablets
DrugBank: Oxerutins (DB15826)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venoruton tablets (control group)
Trial: 19644045
Drug: Budesonide/formoterol (320/9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (320/9 microg) plus tiotropium (18 microg once daily)
Trial: 11430175
Drug: SSRIs (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs (selective serotonin reuptake inhibitors) as first-line treatment for depressive and anxiety disorders
Trial: 11430175
Drug: Newer antidepressants
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer antidepressants (venlafaxine, bupropion, nefazodone, mirtazapine)
Trial: 7932276
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light treatment (2,500 lux) between 0600 and 0800 hours
Trial: 7932276
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light treatment (2,500 lux)
Trial: 15784928
Drug: Intramuscular ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketorolac (30 mg)
Trial: 7491331
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no theophylline treatment)
Trial: 22723577
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure therapy
Trial: 27282690
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment using a short leg cast or splint (Group A)
Trial: 14624026
Drug: Daily dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosage of vitamin C
Trial: 14624026
Drug: Daily dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosage of vitamin E
Trial: 10900277
Drug: Acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine (600 mg orally twice daily) and 0.45 percent saline intravenously
Trial: 8922661
Drug: HRT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT treatment groups
Trial: 30847930
Drug: Oestrogen administration
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen administration (EE)
Trial: 30847930
Drug: Endothelin B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelin B receptor (ETB R) inhibition (BQ-788)
Trial: 30847930
Drug: Lactated Ringer
RxNorm normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer solution alone
Trial: 30021634
Drug: Orlistat treatment
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat treatment for 1-3 months before IVF-ET
Trial: 30021634
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 1-3 months before IVF-ET
Trial: 18775878
Drug: Active group
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active group (discharged 24h after first PM implant or 4-6h after replacement, followed with Home-Monitoring for 4 weeks)
Trial: 10656234
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of thioctic acid (TA) t.i.d. for 3 weeks
Trial: 1523284
Drug: Chlorpromazine (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (12.5 mg orally)
Trial: 1523284
Drug: Chlorpromazine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (25 mg orally)
Trial: 1523284
Drug: Lorazepam (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (2.5 mg orally)
Trial: 4043516
Drug: Furosemide-triamterene combination
RxNorm normalized name: furosemide / triamterene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide-triamterene combination
Trial: 31142081
Drug: Sublingual 5
RxNorm normalized name: melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sublingual 5 mg nifedipine dripping pills
Trial: 31142081
Drug: Sublingual 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual 10 mg nifedipine dripping pills
Trial: 29034961
Drug: Automated intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated intermittent boluses with 16 mg ropivacaine every 2 hours combined with patient-controlled administration
Trial: 29034961
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 8 mg/h (4 ml/h) of ropivacaine combined with patient-controlled administration (2 ml, lockout time 30 min)
Trial: 27061887
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose subcutaneous zoster vaccine
Trial: 27061887
Drug: 1/3 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/3 dose subcutaneous zoster vaccine
Trial: 27061887
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose intradermal zoster vaccine
Trial: 27061887
Drug: 1/3 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/3 dose intradermal zoster vaccine
Trial: 27061887
Drug: 1/10 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/10 dose intradermal zoster vaccine
Trial: 27061887
Drug: 1/27 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/27 dose intradermal zoster vaccine
Trial: 27061887
Drug: All intradermal
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All intradermal doses
Trial: 24659236
Drug: rebamipide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rebamipide (100 mg tid) + LDA (100 mg once-daily)
Trial: 24659236
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + LDA + clopidogrel (75 mg once-daily)
Trial: 16415603
Drug: Propranolol 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 1.0 mg
Trial: 16415603
Drug: Propranolol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 0.5 mg
Trial: 12570169
Drug: Bromocriptine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (7.5 mg continuously) combined with clomiphene citrate (150 mg from day 5 to 9)
Trial: 12570169
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with clomiphene citrate (150 mg from day 5 to 9)
Trial: 12570169
Drug: Bromocriptine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine and placebo treatment
Trial: 9456562
Drug: Group I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I: 38 children (76 eyes) with birth weight from 580 to 1500 g (mean 1158 g)
Trial: 9456562
Drug: Group II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II: 52 children (104 eyes) with birth weight from 1501 to 2450 g (mean 2093 g)
Trial: 2844546
Drug: RX77368 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RX77368 infusion
Trial: 2844546
Drug: Domperidone during
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone during RX77368 infusion
Trial: 31276454
Drug: Alcohol dose
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol dose 1 (0.06%)
Trial: 31276454
Drug: Alcohol dose
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol dose 2 (0.08%)
Trial: 27007062
Drug: N-acetylcysteine (1200-3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (1200-3000 mg/d)
Trial: 11669432
Drug: Remifentanil anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil anaesthesia (boluses and infusion)
Trial: 30362981
Drug: Capacitive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capacitive and resistive electric transfer (CRET) therapy
Trial: 22773282
Drug: Carotenoid supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotenoid supplementation (0.14 mg lutein + 0.0006 mg zeaxanthin)
Trial: 18165564
Drug: Propofol (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (6 mg x kg(‐1) x h(‐1) for 10 min followed by 2.4 mg x kg(‐1) x h(‐1))
Trial: 3537245
Drug: Furosemide (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (single dose)
Trial: 3537245
Drug: Furosemide (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (long-term therapy)
Trial: 29905619
Drug: MMF capsule
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF capsule
Trial: 29905619
Drug: MMF dispersible
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF dispersible tablet
Trial: 27637335
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) - 0.092 g EPA+DHA/kg body weight/day
Trial: 18551124
Drug: Insulin users
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin users (88 participants, 54% of total)
Trial: 18551124
Drug: Insulin users
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin users (after adjustment)
Trial: 10353514
Drug: RRV‐TV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRV‐TV vaccine
Trial: 8626881
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg immediate-release (IR) verapamil every 8 hours
Trial: 8626881
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg controlled-release (CR) formulation once daily
Trial: 8626881
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations (IR and CR)
Trial: 2123907
Drug: conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional therapy (Group C)
Trial: 2123907
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (conventional therapy)
Trial: 6994665
Drug: Metrifonate at
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate at 10 mg/kg body weight for three days
Trial: 6994665
Drug: Metrifonate at
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate at 10 mg/kg body weight for six days
Trial: 28948706
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of bone marrow-derived mononuclear cells (BM-MNCs) 2-8 days after successful reperfusion for AMI added on top of optimal standard of care.
Trial: 23453612
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g amoxicillin antibiotic prophylaxis
Trial: 19781270
Drug: Two-dose steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose steroid combined with two-dose daclizumab and tacrolimus
Trial: 19781270
Drug: Conventional protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional protocol (steroid withdrawn after 3 months)
Trial: 9140670
Drug: Nisoldipine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (0.05 mg intracoronary during procedure, followed by 20 mg/day orally for 6 months)
Trial: 9140670
Drug: Nitrates (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrates (0.8 mg intracoronary during procedure, followed by 80-120 mg/day orally for 6 months)
Trial: 7526025
Drug: Physiologic concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic concentrations of the platelet specific agonist ADP
Trial: 2889217
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg dexchlorpheniramine maleate 3-times daily
Trial: 4686554
Drug: Inhaled aerosols
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled aerosols of prostaglandin F(2)alpha (PGF(2)alpha)
Trial: 4686554
Drug: Inhaled aerosols
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled aerosols of histamine
Trial: 4686554
Drug: Inhaled aerosols
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled aerosols of prostaglandin E(2) (PGE(2))
Trial: 4686554
Drug: Simultaneous inhalation
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous inhalation of a 100-times higher PGE(2) dose with PGF(2)alpha
Trial: 23559676
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (without GH)
Trial: 16914701
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (initial low-dose gentamicin plus either an antistaphylococcal penicillin or vancomycin)
Trial: 14992900
Drug: Bivalirudin (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg/h infusion)
Trial: 14992900
Drug: Heparin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (150 to 300 U/kg bolus) with protamine reversal
Trial: 8489977
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine alone (Control)
Trial: 26133666
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin (ER niacin)
Trial: 23205593
Drug: Standard Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Cognitive Behavioural Therapy (SCBT)
Trial: 23205593
Drug: Enhanced Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Cognitive Behaviour Therapy (ECBT)
Trial: 15972298
Drug: Azathioprine 2
RxNorm normalized name: azathioprine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine 2 mg/kg/day
Trial: 15972298
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid 3.2 g/day
Trial: 12947422
Drug: Ordinary caviar
RxNorm normalized name: Caviar, unspecified
DrugBank: Caviar, unspecified (DB14241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary caviar paste (25 g daily for 3 weeks)
Trial: 12947422
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil enriched caviar paste (25 g daily for 3 weeks)
Trial: 11930370
Drug: Resin-bonded bridges
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin-bonded bridges with grooves in abutment teeth preparation
Trial: 6130952
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg etintidine
Trial: 6130952
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg etintidine
Trial: 27487406
Drug: Oscillatory Biofield
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oscillatory Biofield Therapy (OBFT)
Trial: 24717640
Drug: Atorvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (80 mg, orally once a day for 6 months)
Trial: 22908774
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg administered without cost for 4 months (Group A)
Trial: 22908774
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg administered with cost for 4 months (Group B)
Trial: 22908774
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg administered without cost (Group A)
Trial: 22908774
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg administered with cost (Group B)
Trial: 18333867
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral (14)C‐labelled maraviroc
Trial: 18333867
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg intravenous maraviroc
Trial: 18333867
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral maraviroc
Trial: 15819354
Drug: Test gel
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test gel containing ACP